Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors?

References

• Boulton A JM, Malik R A. Diabetic neuropathy. Med Clin North Am 1998; 82: 909–29
   PubMed Web of Science ®Google Scholar
• Malik R A. Pathology and pathogenesis of diabetic neuropathy. Diabetes Care 1999; 7: 1–8
   Google Scholar
• Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561–8
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53
   PubMed Web of Science ®Google Scholar
• Dyck P J, Davies J L, Wilson D M, Service F J, Melton L J, III, O'Brien P C. Risk factors for severity of diabetic poly-neuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Cure 1999; 22: 1479–86
   PubMed Web of Science ®Google Scholar
• Forrest K YZ, Maser R E, Pambianco G, Becker D J, Orchard T J. Hypertension as a risk factor for diabetic neuropathy. Diabetes 1997; 46: 665–70
   PubMed Web of Science ®Google Scholar
• Cardiovascular risk factors predict diabetic peripheral neuropathy in Type 1 subjects in Europe. The EURODIAB Prospective Complications Study (PCS) Group. Diabetologia 1999; 42: A50–181
   Google Scholar
• Malik R A. Microalbuminuria-pathophysiology, relevance and treatment. Heart Failure Hypertens 1998; 10: 4–6
   Google Scholar
• Maschio G, Alberti D, Janin G, Locatelli F, Mann J FE, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor Benzapril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–45
   PubMed Web of Science ®Google Scholar
• Pawing H -H, Larsen M, Hommel E, Lund-Andersen H. Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive type 1 diabetic patients with background retinopathy. Diabetologia 1989; 32: 440–4
   Google Scholar
• Chaturvedi N, Sjolie A -K, Stephenson J M, Abrahamian H, Kiepes M, Castellarian A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28–31
   PubMed Web of Science ®Google Scholar
• Giannattasio C, Failla M, Piperno A, Grappiolo A, Gamba P, Paleari F, et al. Early impairment of large artery structure and function in Type 1 diabetes mellitus. Diabetologia 1999; 42: 987–94
   PubMed Web of Science ®Google Scholar
• Enderle M -D, Benda N, Schmuelling R -M, Haering H U, Pfohl M. Preserved endothelial function in IDDM patients, but not in NIDDM patients compared with healthy subjects. Diabetes Cure 1998; 21: 271–7
   PubMed Web of Science ®Google Scholar
• Malik R A, Paniagua O, Shaw L, Austin C, Heagerty A M. Resistance vessel function and structure in normotensive patients with type 1 diabetes. Diabetologia 1999; 42: A75–271
   Google Scholar
• Veves A, Akbari C M, Primavera J, Donaghue V M, Zacharoulis D, Chrzan J S, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998; 47: 457–63
   PubMed Web of Science ®Google Scholar
• Jude E B, Boulton A JM, Ferguson M WJ, Appleton I. The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth factor beta 1. Diabetologia 1999; 42: 748–57
   PubMed Web of Science ®Google Scholar
• Hogikyan R V, Wald J J, Feldman E L, Greene D A, Halter J B, Supiano M A. Acute effects of adrenergic-mediated ischemia on nerve conduction in subjects with type 2 diabetes. Metabolism 1999; 48: 495–500
   Google Scholar
• Kihara M, Mitsui M K, Mitsui Y, Okuda K, Nakasaka Y, Takahashi M, et al. Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide. Muscle Nerve 1999; 22: 920–5
   Google Scholar
• Tooke J E. A pathophysiological framework for the pathogenesis of diabetic microangiopathy. Diabetic angiopathy, J E Tooke. Arnold, LondonUK 1999; 187–94
   Google Scholar
• Rayman G, Malik R A, Sharma A K, Day J L. Microvascular response to tissue injury and capillary ultrastructure in the foot skin of Type I diabetic patients. Clin Sci 1995; 89: 467–74
   PubMed Web of Science ®Google Scholar
• Malik R A, Newrick P G, Sharma A K, Jennings A, Ah-See A K, Mayhew T M, et al. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 1989; 32: 92–102
   PubMed Web of Science ®Google Scholar
• Malik R A, Tesfaye S, Thompson S D, Veves A, Sharma A K, Boulton A J, et al. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia 1993; 36: 454–9
   PubMed Web of Science ®Google Scholar
• Yasuda H, Dyck P J. Abnormalities of endoneurial micro-vessels and sural nerve pathology in diabetic neuropathy. Neurology 1987; 37: 20–8
   PubMed Web of Science ®Google Scholar
• Britland S T, Young R J, Sharma A K, Clarke B F. Relationship of endoneurial capillary abnormalities to type and severity of diabetic polyneuropathy. Diabetes 1990; 39: 909–13
   Google Scholar
• Dyck P J, Hansen S, Kames J, O'Brien P, Yasuda H, Windeband A, et al. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci USA 1985; 82: 2513–7
   PubMed Web of Science ®Google Scholar
• Malik R A, Veves A, Masson E A, Sharma A K, Ah-See K, Schady W, et al. Endoneurial capillary abnormalities in mild human diabetic neuropathy. J Neurol Neurosurg Psychiatry 1992; 55: 557–61
   Google Scholar
• Giannini C, Dyck P J. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol 1995; 37: 498–504
   PubMed Web of Science ®Google Scholar
• Newrick P G, Wilson A J, Jakubowski J, Boulton A JM, Ward J D. Sural nerve oxygen tension in diabetes. BM J 1986; 293: 1053–4
   Google Scholar
• Ibrahim S, Harris N D, Radatz M, Selmi F, Rajbhandari S, Brady L. A new minimally invasive technique to show nerve ischaemia in diabetic neuropathy. Diabetologia 1999; 42: 737–42
   Google Scholar
• Tesfaye S, Malik R, Harris N, Jakubowski J, Mody C, Ward J D. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 1996; 39: 329–35
   Google Scholar
• Theriault M, Dort J, Sutherland G, Zochodne D W. Local human sural nerve blood flow in diabetic and other polyneuropathies. Bruin 1997; 120: 1131–8
   Google Scholar
• Tesfaye S, Harris N, Jakubowski J J, Mody C, Wilson R M, Rennie I G, et al. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 1993; 36: 1266–74
   PubMed Web of Science ®Google Scholar
• Low P A, Tuck R R, Dyck P J, Schmelzer J D, Yao J K. Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc Natl Acad Sci USA 1984; 81: 6894–8
   Google Scholar
• Low P A, Schmelzer J D, Ward K K, Curran G L, Poduslo J F. Effect of hyperbaric oxygenation on normal and chronic streptozotocin diabetic peripheral nerves. Exp Neurol 1985; 99: 201–12
   Google Scholar
• Robertson S, Cameron N E, Cotter M A. The effect of the calcium antagonist nifedipine on peripheral nerve function in streptozotocin-diabetic rats. Diabetologia 1992; 35: 1113–7
   Google Scholar
• Cameron N E, Cotter M A, Ferguson K, Robertson S, Radcliffe M A. Effects of chronic alpha-adrenergic receptor blockade on peripheral nerve conduction, hypoxic resistance, polyols, Na+-K+-ATPase activity and vascular supply in STZ-D rats. Diabetes 1991; 40: 1652–8
   Google Scholar
• Hotta N, Kakuta H, Fakasawa H, Koh N, Sakakibara F, Komori H, et al. Effect of niceritrol on streptozotocin-induced diabetic neuropathy in rats. Diabetes 1992; 41: 587–91
   PubMed Web of Science ®Google Scholar
• Ristic H, Wiley J W, Hall K E, Sima A AF. Failure of nimodipine to prevent or correct the long-term nerve conduction defect and increased neuronal Ca(2+) currents in the diabetic BB/W rat. Diabetes Res Clin Pract 1996; 32: 135–40
   Google Scholar
• Cotter M A, Cameron N E. Correction of neurovascular deficits in diabetic rats by beta2-adrenoceptor agonist and alphal-adrenoceptor antagonist treatment: interactions with the nitric oxide system. Eur J Pharmacol 1998; 343: 217–23
   Google Scholar
• Cameron N E, Cotter M A, Robertson S. Angiotensin converting enzyme inhibition prevents the development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992; 35: 12–8
   Google Scholar
• Maxfield E K, Cameron N E, Cotter M A, Dines K C. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats. Diabetologia 1993; 36: 1230–7, 53
   Google Scholar
• Cameron N E, Cotter M A. Effects of a nonpeptide endo-thelin-1 ETA antagonist on neurovascular function in diabetic rats: interaction with the renin-angiotensin system. J Pharmacol Exp Ther 1996; 278: 1262–8, 54
   Google Scholar
• Qiang X, Satoh J, Sagara M, Fukazawa M, Masuda T, Sakata Y, et al. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia 1998; 41: 1321–6
   PubMed Web of Science ®Google Scholar
• Walker A B, Chattington P D, Buckingham R E, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48: 1448–53
   PubMed Web of Science ®Google Scholar
• Cameron N E, Cotter M A, Jack A M, Basso M D, Hohman T C. Protein kinase C effects on nerve function, perfusion, Na+,K+-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999; 42: 1120–30
   PubMed Web of Science ®Google Scholar
• Nakamura J, Kato K, Hamada Y, Nakayama M, Chaya S, Nakashima E, et al. Protein kinase C-p-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48: 2090–5
   PubMed Web of Science ®Google Scholar
• Young M J, Veves A, Walker M G, Boulton A JM. Correlations between nerve function and tissue oxygenation in diabetic patients: further clues to the aetiology of diabetic neuropathy. Diabetologia 1992; 35: 1146–50
   PubMed Web of Science ®Google Scholar
• Veves A, Donaghue V M, Sarnow M R, Giurini J M, Campbell D R, LoGerfo F W. The impact of reversal of hypoxia by revascularization on the peripheral nerve function of diabetic patients. Diabetologia 1996; 39: 344–8
   Google Scholar
• Akbari C M, Gibbons G W, Habershaw G M, LoGerfo F W, Veves A. The effect of arterial reconstruction on the natural history of diabetic neuropathy. Arch Surg 1997; 132: 148–52
   Google Scholar
• Horrobin D. Gamma-linolenic acid in the treatment of diabetic neuropathy. Diabetic neuropathy, A JM Boulton. Marius Press, CarnforthUK 1997; 183–95
   Google Scholar
• Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Moller W, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alphalipoic acid): a two year multicenter randomised double-blind placebo-controlled trial (ALADIN-11). Free Radic Res 1999; 31: 171–9
   PubMed Web of Science ®Google Scholar
• Curzen N C, Timmis A. Endothelial dysfunction in chronic heart failure. Controversies in the management of heart failure, A Coats, J GF Cleland. Churchill Livingstone, LondonUK 1997; 25–40
   Google Scholar
• Vanhoutte P M, Feletou M, Boulanger C M, Hoffner U, Rubanyi G M. Existence of multiple endothelium-derived relaxing factors. Endothelium-derived hyperpolarizing factor, P M Vanhoutte. Harwood Academic Publishers, Amsterdamthe Netherlands 1996; 1–10
   Google Scholar
• Cooper M E, Allen T J, O'Brien R C, Papazoglou D, Clarke B E, Jerums G, et al. Nephropathy in model combining genetic hypertension with experimental diabetes. Enalparil versus hydralazine and metoprolol therapy. Diabetes 1990; 39: 1575–9
   PubMed Web of Science ®Google Scholar
• Cooper M E, Rumble J, Komers R, He-Cheng D, Jandeleit K, Sheung-To C. Diabetes associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 1994; 43: 1221–8
   PubMed Web of Science ®Google Scholar
• Zuanetti G, Latini R, Maggioni A P, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96: 4239–45
   PubMed Web of Science ®Google Scholar
• Kontopoulos A G, Athyros V G, Didangelos T P, Papageorgiou A A, Avramidis M J, Mayroudi M C, et al. Effect of chronic Quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997; 20: 355–61
   PubMed Web of Science ®Google Scholar
• Reja A, Tesfaye S, Harris N, Ward J D. Improvement in nerve conduction and quantitative sensory tests after treatment with lisinopril. Diabetic Med 1995; 12: 307–9
   PubMed Web of Science ®Google Scholar
• Al-Memar A, Wimalaratna H SK, Millward B A. Lisinopril improves nerve function in insulin-dependent diabetic patients with neuropathy: a preferential effect on small fibres. Diabetic Med 1996; 13(Suppl 2)S38
   Google Scholar
• Malik R A, Williamson S, Abbott C A, Carrington A L, Iqbal J, Schady W, et al. Effect of angiotensin-converting enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial:. Lancet 1998; 352: 1978–81
   PubMed Web of Science ®Google Scholar